Research Article |
Corresponding author: Hayder Adnan Fawzi ( haider-pharm@almustafauniversity.edu.iq ) Academic editor: Milen Dimitrov
© 2024 Rashad M. Kaoud, Mustafa Hasan Alwan, Mohammed Amran, Hayder Adnan Fawzi.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Kaoud RM, Alwan MH, Amran M, Fawzi HA (2024) Design and optimization of pantoprazole sodium mucoadhesive hydrogel microcapsules for the healing of peptic ulcers. Pharmacia 71: 1-14. https://doi.org/10.3897/pharmacia.71.e118323
|
Hydrogels have gained much focus as a gastro-retentive technology for drug delivery. The current study aimed to design an oral mucoadhesive sustained-release dosage form to lower peptic ulcer complications (PUC). Using the Box-Behnken statistical design, the preparation method was developed by incorporating pantoprazole sodium (PZS) into hydrogel microcapsules (HGMC). The PZS was incorporated into the HGMC via an ion gelation technique, with sodium alginate as the gelling agent, calcium chloride as the crosslinking agent, and chitosan as the agent for sustained release.
The optimized formulation of PZS-HGMC showed a diameter of 2.506 mm, a swelling rate of 838.2%, and an encapsulation efficiency of 93.8%. Scanning electron microscopy images revealed the microcapsules’ spherical shape. The in vitro release of the PZS from the HGMC after two hours in a simulated gastric fluid was 13.2%1±0.08%, compared with the apparent solubility of the pure PZS under the same conditions (95.24%±3.2%). After 24 hours, the percent of PZS released from the optimized formula was 69.84±2.4%, which indicates a sustained release pattern. The results from the in vivo study demonstrated improved healing of the induced ulcers in rats when treated with the PZS-HGMC formulation as compared to the standard PZS therapy; therefore, the obtained mucoadhesive HGMC was considered a potential drug delivery strategy for PUC therapy.
anti-ulcerogenic effect, Box-Behnken design, histopathological analysis, in vitro release
A peptic ulcer is defined as a disruption in the mucosal lining of the gastrointestinal system, specifically in the stomach and upper part of the small intestine, caused by the release of acid or pepsin (
Pantoprazole sodium (PZS) is an effective PPI; it acts by irreversibly binding the parietal cells’ proton pump, which will hinder the main source of acid production in the stomach (
PZS possesses excellent permeability, solubility, and absolute bioavailability (77%) (
Currently, PZS is available in such standard-approved formulations as tablets (EC polymer: methacrylic acid-ethyl acrylate copolymer (1:1) and controloc control), oral suspension (granules, enteric-coated polymer (methacrylic acid copolymer), and powder for solutions for injections (such as sodium hydroxide) (
PUC can be treated in several ways, including using mucoadhesive HGMC drug delivery systems. HGMC have been studied as a potential gastroprotective dosage form because of their capacity to increase the bioavailability of PZS when taken orally by serving as a sustained-release dosage form (
This study aims to formulate an oral mucoadhesive sustained-release dosage form containing pantoprazole sodium hydrogel microcapsules (PZS-HGMC) using the Box-Behnken design and then undergo characterization studies, an in vivo study (including histopathological examination), and an in vitro release study for the optimized PZS-HGMG formula.
Pantoprazole sodium, sodium alginate, and chitosan were gifted by Al-Hikma Pharmaceuticals (Cairo, Egypt). Hydrochloric acid (HCl) and calcium chloride (anhydrous fine GRG 90%) were purchased from the Al-Nasr Company for Pharmaceuticals (Cairo, Egypt). Generally, all the chemicals used were of analytical grade.
The Box-Behnken statistical design with three factors, three levels, and 15 runs was chosen for the optimization analysis. Theoretically, the experimental design consists of points at the midpoint of each edge and the replicated center point of the multi-dimensional cube.
The dependent and independent variables in the experimental design of the microcapsules (MC) formulated by sodium alginate (SAT) and coated with chitosan (CTN) are presented in Table
Yo = b0+ b1X1+ b2X2+ b3X3+b12X1X2+ b13X1X3 + b23X2X3b11X21+b22X22+b33X23
Factors | Independent variables | Low (-1) | Medium (0) | High (+1) | |
---|---|---|---|---|---|
X1 | Sodium Alginate (SAT) | % | 1 | 2 | 3 |
X2 | Calcium Chloride (CaCl2) | % | 2 | 3 | 4 |
X3 | Chitosan (CTN) | % | 0.1 | 0.3 | 0.5 |
Response | |||||
Y1 | Particle Diameter | mm | |||
Y2 | Swelling (SW%) | % | |||
Y3 | Encapsulation Efficiency (EE%) | % |
Y0 is the dependent variable; b0 is an intercept; b1 to b33 are regression coefficients computed from the observed experimental values of Y; and X1, X2, and X3 are the coded levels of independent variables. X1X2 and Xi2 (i = 1, 2, or 3) represent the interaction and quadratic terms, respectively.
The primary constituents of the PZS-HGMG include PZS (20 mg), SAT, CTN, and calcium chloride (CaCl2). These choices were made based on the initial experiments for the formulation of PZS-HGMG. The experimental design investigated the connection between the independent variables and their responses and interactions in an effective model. It involved three variables and three responses. While the independent variables were the concentration of SAT (X1), the concentration of CaCl2 (X2), and the concentration of CTN (X3), the measured dependent variables were particle diameter (Y1), swelling degree (Y2), and encapsulation efficiency (Y3), as represented in Table
The pantoprazole-loaded hydrogel microcapsules of alginate core and chitosan coating were prepared using the ion gelation method with some modifications (
As a first stage of formulation, SAT (1%–3% w/v) was dissolved in deionized water (20 mL) and stirred (900 rpm) at 25 °C. Then PZS 20 mg was dissolved in deionized water (10 mL) as the first solution. The second solution consisted of CTN (0.1%–0.5%) and CaCl2 (2%–4%) dissolved in a 1% v/v acetic acid solution, which was used as a coagulation fluid. The first solution was molded into a second homogenous solution with 0.1 N HCl, and the pH was adjusted to 5±0.1. A 1 mL/min pumping rate was used to keep the combined flow constant. After being stirred in the fluid for 20 minutes, PZS-HGMG was formulated. The PZS-HGMG were filtered, washed, and dried at 25±0.5 °C (
Optimization employing Box-Behnken design
The optimized formula was chosen according to the response to the desirability of variables (by maximizing particle diameter, swelling, and encapsulation efficiency). Physicochemical, in vitro, and in vivo analyses were conducted for the optimized formula.
It was validated statistically by constructing quadratic equations for the diameter of the response, SW% studies, and the EE% (Y1, Y2, and Y3), respectively.
The PZS-HGMC were measured for diameter with a micrometer screw gauge, and the mean was then calculated (
The SW% of the HGMC was investigated via the immersing method (
The drug content of the PZS-HGMG was directly measured. The PZS-HGMG (200 mg) was carefully weighed and crushed. The PZS-HGMG were mixed with deionized water (10 mL) for a full day at 25±0.5 °C. Then, the solution was filtered through a nano-filter syringe. The PZS concentration was detected spectrophotometrically using the UV-visible spectrophotometer (Shimadzu, Japan) at 283 nm. The EE% was detected using the following equation (Umaredkar et al. 2020):
RA and TA are the resulting and theoretical amounts of PZS found in the PZS-HGMG, respectively. The results were repeated in triplicate.
The morphologies and surface of the PZS-HGMG were investigated using SEM (Agilant 8500 FE, Japan) (
Before submitting samples for FTIR evaluation, a pestle and mortar were used to reduce the PZS-HGMG to a powder. The FTIR probe examined the sample (JASCO FTIR Model 6600, Tokyo, Japan). The range was selected from 400 to 4000 cm-1 with 95% transmittance. Interactions can be detected, and functional group alterations can be identified using FTIR spectral analysis (FTIR spectrophotometer at a scanning number of 8 with the KBr sampling method) (
Some differential scanning calorimetry (DSC) studies were applied using DSC 60 TASYS Software (Shimadzu, Japan). The dry MCs used in the DSC trial varied from 3 to 7 mg. The sample was analyzed in a nitrogen flow with a 25–300 °C temperature, and the scan rate was 10 °C/min. The DSC detects crystallinity changes, melting points, and drug-excipient-adsorbent interactions (
The PZS release experiment used a USP apparatus type II (Copaly, United Kingdom) at 100 rpm and 37 °C. Then 20 mg of PZS-HGMG and PURE PZS were placed in hard gelatin capsules, and then the capsules were placed in 0.1N HCl (pH 1.2) to simulate the stomach environment over 24 hours. At each of the 24-hour intervals (10 intervals), 5 mL aliquots were removed and refilled with fresh dissolution media. The PZS concentration of each sample was determined at 283 nm spectrophotometrically (Shimadzu, Japan). The test was conducted in triplicate (
The in vivo study was prepared following the ARRIVE Guidelines 2.0. Male Wistar rats (weighted around 180–200 g and ages 3–5 months) were received from the animal facility in the Pharmacy Department at Ashur University College. They were maintained at 25 °C and a light/dark cycle (12 hours light and 12 hours dark). The animals received commercial pellet feed and had free access to water. They were acclimated for 10 days before starting the experiment at the same center where the rats were obtained.
For sample size computation, the program G Power was utilized (
The study modules employed a randomized block design. The mice were categorized into five distinct blocks. Block one (G1) received their treatment plan. Then, in order in subsequent weeks, Block two (G2), Block three (G3), Block four (G4), and Block five (G5) commenced their respective treatments. Details of the animal allocation and drug dosing are illustrated in Table
Indomethacina | Drug received (eight weeks) | Duration | |
---|---|---|---|
G1 | Did not receive | normal saline by gastric gavage | 15 days |
G2 ( |
Received | normal saline by gastric gavage | 15 days |
G3 | Received | blank HGMC by gastric gavage | 15 days |
G4 ( |
Received | PZS pure (20 mg/kg) by gastric gavage | 15 days |
G5 ( |
Received | PZS-HGMC optimized formula (20 mg/kg) by gastric gavage | 15 days |
Induction of ulcers by indomethacin (IMN) was done (induction of gastric ulcers was done following previous studies) (
In each group, the rats received the optimized formula once per day for 15 days. On the 16th day, all animals had a period of fasting lasting 10 hours. Subsequently, they were subjected to intraperitoneal (IP) anesthesia with a dosage of 80 mg/kg of ketamine (Ketamine 10%, Alfasan Nederland BV, Holand) and 10 mg/kg of xylazine (XYL-M2, VMD® Livestock Pharma, Belgium). After undergoing complete anesthesia, the rats were euthanized using carbon dioxide (
The stomachs of the rats were extracted and macroscopically evaluated for bleeding ulcers. The number and intensity of lesions per piece of gastric tissue were recorded microscopically. Lesions were assessed visually after opening the stomach, cleansing with ice-cold saline, and coating with filter paper (
The pieces of gastric tissue were preserved by immersion in 10% formalin and subsequent fixation in paraffin. Pieces of 5–6 µm thickness were colored with hematoxylin and eosin. The Sydney system was applied to assess microscopic changes in the gastric mucosa, including chronic lesions, dropout gland (atrophy) regions, and intestinal metaplasia (
Following CPCSEA regulations, the Institutional Animal Ethics Committee authorized the experimental protocols for research project number RP62 (date: 2 December 2022).
Experimental results are the mean±standard deviation (SD). The significance of differences was tested by analyzing variance (ANOVA). Differences were considered statistically significant at P ≤ 0.05.
Realizing the complexity of producing pharmaceutical formulations is made easier by the numerous benefits and the adaptability of the design. Several independent parameters govern the number of experiments required, whereas the responses for every trial are established and the multiple regression analysis is performed.
The current study employs a straightforward design with just three independent variables across three distinct levels of experimentation. All batches of the formulations were made as planned and tested for various responses. Using ANOVA (Analysis of Variance), the present study investigated each variable alone and interacted with the other responses to improve the outcomes. Using Design Expert® software and an ANOVA analysis, it produced 15 different formulations. It validated them statistically by constructing quadratic equations for the diameter of the response, SW% studies, and the EE% (Y1, Y2, and Y3), respectively, as illustrated by Table
Experimental design for the formulations of PZS-HGMC using a Box-Behnken design.
Run | SAT (%) | CaCl2 (%) | CTN (%) | SAT (%) | CaCl2 (%) | CTN (%) | Diameter (mm) | Swelling (SW%) | (EE%) |
---|---|---|---|---|---|---|---|---|---|
F1 | -1 | -1 | 0 | 1.0 | 2.0 | 0.3 | 1.6±0.20 | 410.0±43.5 | 88.0±2.0 |
F2 | 1 | -1 | 0 | 3.0 | 2.0 | 0.3 | 2.5±0.26 | 735.0±26.6 | 92.0±1.7 |
F3 | -1 | 1 | 0 | 1.0 | 4.0 | 0.3 | 1.3±0.26 | 460.0±27.6 | 90.0±2.6 |
F4 | 1 | 1 | 0 | 3.0 | 4.0 | 0.3 | 2.5±0.10 | 800.0±30.0 | 93.0±1.0 |
F5 | -1 | 0 | -1 | 1.0 | 3.0 | 0.1 | 1.4±0.26 | 470.0±30.8 | 89.0±2.0 |
F6 | 1 | 0 | -1 | 3.0 | 3.0 | 0.1 | 2.3±0.10 | 740.0±30.3 | 93.0±3.0 |
F7 | -1 | 0 | 1 | 1.0 | 3.0 | 0.5 | 1.3±0.17 | 490.0±26.5 | 87.0±2.6 |
F8 | 1 | 0 | 1 | 3.0 | 3.0 | 0.5 | 2.3±0.20 | 840.0±55.0 | 94.0±3.0 |
F9 | 0 | -1 | -1 | 2.0 | 2.0 | 0.1 | 2.3±0.10 | 500.0±39.0 | 90.0±3.0 |
F10 | 0 | 1 | -1 | 2.0 | 4.0 | 0.1 | 2.1±0.17 | 520.0±29.4 | 91.0±2.6 |
F11 | 0 | -1 | 1 | 2.0 | 2.0 | 0.5 | 2.2±0.10 | 500.0±26.5 | 90.0±3.5 |
F12 | 0 | 1 | 1 | 2.0 | 4.0 | 0.5 | 2.2±0.10 | 520.0±27.9 | 91.0±2.6 |
F13 | 0 | 0 | 0 | 2.0 | 3.0 | 0.3 | 2.0±0.17 | 510.0±32.9 | 91.0±2.0 |
F14 | 0 | 0 | 0 | 2.0 | 3.0 | 0.3 | 2.0±0.20 | 510.0±26.5 | 91.0±2.6 |
F15 | 0 | 0 | 0 | 2.0 | 3.0 | 0.3 | 2.0±0.30 | 510.0±33.0 | 91.0±1.7 |
The resulting PZS-HGMG had diameters ranging from 1.3 to 2.5 mm by vernier caliper (
Table
The PZS-HGMG showed swelling, resulting in MC with a small amount of SAT bursting after two hours of testing. The Na+ ion in the used buffer and the Ca2+ ion in the cavity of Ca-alginate microcapsules are involved in the ion exchange mechanism (
The EE% was 87.0 to 94.0%; the greater EE% of the SAT–CTN microcapsules may be attributed to the more porous structure (
The optimized PZS-HGMG formula was developed using the indicated concentrations of variables from an overlay plot to ensure the model’s accuracy. The effect of changing the concentrations of CaCl2, SAT, and CTN on response parameters (PZ, SW%, and EE%) was examined. The desirability of the optimized formula in this experiment would have maximum EE%, SW%, and PZ in the range.
By fixing the effects of one parameter, one can examine the effects of the other two parameters with PS; thus, by holding the CTN concentration constant, SAT has a direct relationship with PS, and CaCl2 did not affect PS (Fig.
By holding the CaCl2 concentration constant, PS appeared to be directly associated with SAT, while CTN did not affect PS (Fig.
By holding the SAT concentration constant, both CTN and CaCl2 have a direct relationship with PS (Fig.
The overall adjusted R2 of the model was 99.11%, with SAT showing 84.75% contribution of the final model (p-value < 0.001), with SAT (r = 0.5, p-value < 0.001), CaCl2 (r = -0.0625, p-value = 0.006), SAT*SAT (r = -0.2, p-value < 0.001), CaCl2*CaCl2 (r = 0.175, p-value < 0.001), and SAT*CaCl2 (r = 0.075, p-value = 0.012) are the significant coefficients in the final model:
Particle size (mm) = 2.787 + 1.038 Alginate − 1.338 CaCl2 − 1.437 Chitosan − 0.2000 Alginate * Alginate + 0.1750 CaCl2 * CaCl2 + 0.625 Chitosan * Chitosan + 0.0750 Alginate * CaCl2 + 0.1250 Alginate * Chitosan + 0.2500 CaCl2 * Chitosan
By fixing the effects of one parameter, one can examine the effects of the other two parameters with SW%; thus, by holding the CTN concentration constant, SAT has a direct relationship with SW%, and CaCl2 did not affect SW% (Fig.
By holding the CaCl2 concentration constant, SW% appeared directly associated with SAT, while CTN did not affect SW% (Fig.
By holding the concentration of SAT constant, both CTN and CaCl2 have a direct relationship with SW% (Fig.
The overall adjusted R2 of the model was 97.0%, with SAT showing a 78.92% contribution to the final model (p-value < 0.001), with SAT (r = 160.63, p-value < 0.001), and SAT*SAT (r = 108.1, p-value < 0.001) as the significant coefficients in the final model:
Swelling (%) = 509 − 313.1 Alginate + 113.1 CaCl2 − 378 Chitosan + 108.1 Alginate * Alginate − 16.9 CaCl2 * CaCl2 + 422 Chitosan * Chitosan + 3.8 Alginate * CaCl2 + 100.0 Alginate * Chitosan - 0.0 CaCl2 * Chitosan
By fixing the effects of one parameter, one can examine the effects of the other two parameters with EE%. By holding the CTN concentration constant, SAT and CaCl2 have a direct relationship with EE% (Fig.
Holding the CaCl2 concentration constant, EE% appeared to be directly associated with SAT and CTN (Fig.
By holding the concentration of SAT constant, both CTN and CaCl2 have a direct relationship with EE% (Fig.
The overall adjusted R2 of the model was 87.13%, with SAT showing an 82.77% contribution to the final model (p-value < 0.001), with SAT (r = 2.25, p-value < 0.001), and CaCl2 (r = 0.625, p-value = 0.046) as the significant coefficients in the final model:
Encapsulation efficacy (%) = 82.75 + 1.88 Alginate + 2.62 CaCl2 − 4.38 Chitosan − 0.000 Alginate * Alginate − 0.250 CaCl2 * CaCl2 − 6.25 Chitosan * Chitosan − 0.250 Alginate * CaCl2 + 3.75 Alginate * Chitosan + 0.00 CaCl2 * Chitosan
The concentration of SAT increased, and the diameter increased (Fig.
CaCl2 change, when considered in terms of change in SAT, showed no significant effect, which indicates SAT has more effect on the PZ at all concentrations of CaCl2; however, the effect on CaCl2 change when examined against the change in CTN showed variability, in which a larger PS was achieved with low concentrations of CaCl2 and higher concentrations of CTN and the lowest PS was achieved with medium concentrations of CaCl2 and the lowest concentrations of CTN. It is evident from the model graphs displayed in Fig.
Dissolution of the PZS-HGMG formulated in a low CaCl2 solution occurred sooner than in PZS-HGMG formulated in CaCl2 solutions of higher concentrations, and the maximum SW ratios rose with the increase in CaCl2 concentration at pH 1.2. The concentration of Ca2+ during the formulation of PZS-HGMG may improve their crosslinking density. This observation is consistent with those of (
It is blatantly obvious in Fig.
As CTN concentration increases, the resulting formulation’s diameters rise (
The SW% index grew dramatically with rising CTN concentrations at pH 1.2. The raised concentration of CTN led to a raised SW% of different formulae (Fig.
The impacts of CTN concentration on the diameter and EE% of different formulas may explain why a reduction in CTN concentration led to a decline in EE%. The results are shown in Fig.
The optimized formula was chosen by the numerical optimization of Design Expert® software based on the desirability factor’s proximity to 1 (Fig.
These values predict a 2.506 mm diameter, 838.249% SW, and 93.7645% EE. Further characterization confirmed that the optimized formula was valid and determined to be within acceptable ranges.
Fig.
Infrared spectroscopic analysis for PZS, SAT, CTN, physical mixture HGMC, and the PZS-HGMC optimized formula is shown in Fig.
The DSC thermograms for PZS, SAT, CTN, the optimized formula physical mixture, and the PZS-HGMC optimized formula are shown in Fig.
Both the free PZS (R2adj = 0.985) and PZS-HGMC (R2adj = 0.935) releases followed first-order kinetics (DDSolver 1.0® performed analysis). Fig.
Macroscopic evaluation of the examined rats’ gastric tissues is shown in Fig.
When given orally (30 mg/kg), IMN caused severe bleeding sores, most of which were in the gastric glandular mucosa and very few, if any, in the antrum (
There were fewer stomach ulcers after administering free PZS to the rats (Fig.
On the other hand, medication with a PZS-HGMC optimized formula (Fig.
During the study, the rats in the medicated groups were healthier and behaved normally. The results showed that the medication of animals with PZS-HGMC provided more protection against PUC than medication with free PZS. This could be because the medicine is released slowly over time, retaining a potent concentration of the PZS for a longer period.
The variations in the gastric tissues of the tested rat groups were confirmed through histopathological evaluation. Fig.
Eccentric nuclei and pale eosinophilic vacuoles in the cytoplasm characterize the parietal cells that make up the top half of the stomach. On the contrary, the IMN-medicated positive control group (G2) (Fig.
These findings demonstrated the chronic inflammation and acute stage of the lesion. The findings also showed the gastric tissue to be highly inflamed for the INM-medicated group (G3) receiving the blank MC (Fig.
In the present study, the oral treatment of IMN-induced PUC in experimental rats with the optimized PZS-HGMC formula for 15 successive days significantly accelerated the recovery of induced PUC compared to the oral treatment with free PZS. SEM photographs showed spherical, smooth surfaces for PZS-HGMG. The FTIR study confirmed the interaction between PZS molecules and the CTN network. DSC showed the dispersion of PZS in the PZS-HGMG network. The effect of different independent variables on diameter, SW%, and EE% was studied for different formulae.
The PZS-HGMC optimized formula has been further examined. The in vitro release of the optimized formula was compared with free PZS in acidic media for 24 hours. The results indicated the release of 95.24±3.2% of free PZS in the first two hours, compared to 13.21±0.08% of the optimized formula. After 24 hours, approximately 69.84±2.4% of PZS was released from the optimized formula. In conclusion, the PZS-HGMC optimized formula exhibited a sustained release effect and improved the healing of PUC compared to free PZS.
The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.
The authors have no relevant financial or non-financial interests to disclose.
Not applicable.